HICKS KERRY R 4

What Happened

• Kerry R. Hicks, a director of TriSalus Life Sciences, was granted a total of 84,604 shares on May 14, 2026. The filing shows 28,201 shares acquired outright at $0.00 and 56,403 shares reported as a derivative award (RSUs) at $0.00; total reported value at grant = $0. These are awards/compensation, not open‑market purchases or sales.

Key Details

• Transaction date: 2026-05-14; Form 4 filed 2026-05-15 (timely reporting).
• Prices: $0.00 per share; total reported consideration = $0.
• Vesting: The RSU award vests in full on May 14, 2027, subject to Hicks’ continued service (per footnote).
• Shares owned after transaction: not specified in the excerpt provided.
• Relevant footnotes: F1 describes the RSU award payable in common stock and one‑year vesting; F2–F4 note Hicks’ relationships to entities/trusts (managing member/trustee/custodian) and disclaimers of beneficial ownership except for pecuniary interest.
• Filing timeliness: Reported the next day; no late filing indicated.

Context

• RSUs are a promise to deliver shares upon vesting; the 56,403 derivative units here are not immediately tradable stock but will convert to common shares if/when they vest. The 28,201 shares reported as acquired appear to be granted rather than purchased.
• Awards are compensation and should be viewed differently than purchases or sales; they do not by themselves indicate the insider’s current market view.
• Footnotes indicate some of Hicks’ other holdings are held through trusts or entities and that he disclaims beneficial ownership of certain securities except for his pecuniary interest.